Literature DB >> 19072387

Role of cannabinoid receptors in the control of gastrointestinal motility and perception.

Jean Fioramonti1, Lionel Bueno.   

Abstract

The identification of endocannabinoids and cannabinoid CB1 receptors in key areas of the intestinal wall, such as cholinergic neurons, supports a role for cannabinoids in the control of gastrointestinal motility. Activation of CB1 receptors inhibits the peristaltic reflex and slows down gastrointestinal and colonic transit. Endocannabinoids play an important inhibitory role in the control of the occurrence of transient lower esophageal sphincter relaxations. Cannabinoid receptor agonists inhibit gastric emptying and intestinal motility in humans. There is strong anatomical support for a role of CB1 receptors in the control of gastrointestinal perception, since these receptors have been identified in key sites of the neuronal circuitry involved in the transmission of visceral pain. Experimental data indicate a visceral antinociceptive action of cannabinoid receptor agonists, which remains to be confirmed in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19072387     DOI: 10.1586/17474124.2.3.385

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  7 in total

Review 1.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Authors:  Cecilia J Sorensen; Kristen DeSanto; Laura Borgelt; Kristina T Phillips; Andrew A Monte
Journal:  J Med Toxicol       Date:  2016-12-20

Review 2.  The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.

Authors:  Zubair Malik; Daniel Baik; Ron Schey
Journal:  Curr Gastroenterol Rep       Date:  2015-02

Review 3.  Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases.

Authors:  Rudolf Schicho; Martin Storr
Journal:  Can J Gastroenterol       Date:  2011-07       Impact factor: 3.522

Review 4.  Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?

Authors:  Vicente Martínez; Amaia Iriondo De-Hond; Francesca Borrelli; Raffaele Capasso; María Dolores Del Castillo; Raquel Abalo
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 5.  A potential role for GPR55 in gastrointestinal functions.

Authors:  Rudolf Schicho; Martin Storr
Journal:  Curr Opin Pharmacol       Date:  2012-10-10       Impact factor: 5.547

Review 6.  Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.

Authors:  Rachel D Moloney; Siobhain M O'Mahony; Timothy G Dinan; John F Cryan
Journal:  Front Psychiatry       Date:  2015-02-16       Impact factor: 4.157

Review 7.  Endocannabinoid-related compounds in gastrointestinal diseases.

Authors:  Marcella Pesce; Alessandra D'Alessandro; Osvaldo Borrelli; Stefano Gigli; Luisa Seguella; Rosario Cuomo; Giuseppe Esposito; Giovanni Sarnelli
Journal:  J Cell Mol Med       Date:  2017-10-09       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.